Bluejay Diagnostics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 27, 2024, details a material definitive agreement entered into by Bluejay Diagnostics, Inc. (the "Company"). The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Acton, MA. The report covers a firm commitment underwritten public offering (the "Offering") that closed on June 28, 2024.
Key Financial Metrics and Transaction Details
- Offering Structure: The Company sold 5,368,098 Units, each consisting of one share of common stock (or a Prefunded Warrant), two Class C Warrants, and one Class D Warrant.
- Unit Composition: Of the total Units sold, 577,073 included shares of common stock, while 4,791,025 included Prefunded Warrants. Additionally, 1,443,025 Prefunded Warrants were exercised on the day of closing.
- Over-Allotment: The Underwriter partially exercised its over-allotment option for an additional 678,674 Class C Warrants and 339,337 Class D Warrants.
- Underwriting Costs: The Underwriter (Aegis Capital Corp.) received an underwriting discount of 8.5% of the public offering price. The Company also agreed to a $75,000 non-accountable expense allowance and reimbursement of up to $170,000 for legal fees.
- Debt Repayment: The Company intends to use $2.3 million of the net proceeds to repay outstanding debt due upon consummation of the offering.
Material Changes and Use of Proceeds
The primary material change is the significant capital raise and the resulting increase in outstanding equity and warrant instruments. The net proceeds from the Offering are designated for:
- Repayment of $2.3 million in outstanding debt.
- Funding matters related to obtaining FDA approval, including clinical studies.
- Other research and development activities.
- General working capital needs.
Guidance, Risks, and Contingencies
Warrant Stockholder Approval: The value and exercisability of the Class C Warrants and certain adjustment provisions of the Class D Warrants are contingent upon "Warrant Stockholder Approval." If this approval is not obtained, the Class C Warrants will not be exercisable, and the Class D Warrants may have substantially less value.
Warrant Terms:
- Class C Warrants: Initial exercise price of $1.96 per share. Not exercisable until Warrant Stockholder Approval occurs. Subject to price resets and adjustments upon reverse stock splits or future issuances at prices below the initial exercise price.
- Class D Warrants: Immediately exercisable. Exercise price and share count are subject to adjustment based on a rolling five-day weighted average price of the common stock, subject to floor prices.
- Prefunded Warrants: Immediately exercisable (subject to beneficial ownership caps of 4.99% or 9.99%) with a remaining exercise price of $0.0001 per share.
Key Facts for Investor Verification
- Verify the status of the "Warrant Stockholder Approval" required to make Class C Warrants exercisable and to activate certain Class D Warrant adjustments.
- Confirm the exact net proceeds received after deducting the 8.5% underwriting discount and expense reimbursements.
- Monitor the dilution impact from the 4,791,025 Prefunded Warrants and the associated Class C and Class D Warrants.
- Track the Company's progress in utilizing proceeds for FDA approval and clinical studies as stated in the use of proceeds.